

3724176\_1.txt  
SEQUENCE LISTING

<110> Shimadzu Corporation  
National Cancer Center

<120> Method for Quantifying a Monoclonal Antibody

<130> PH-6200-PCT

<160> 14

<170> PatentIn version 3.5

<210> 1  
<211> 449  
<212> PRT  
<213> Artificial

<220>  
<223> antibody heavy chain

<400> 1

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Arg  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Asn Tyr  
20 25 30

Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

Ala Thr Ile Ser Ser Ala Ser Thr Tyr Ser Tyr Tyr Pro Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Leu Tyr Tyr Cys  
85 90 95

Gly Arg His Ser Asp Gly Asn Phe Ala Phe Gly Tyr Trp Gly Gln Gly  
100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe  
115 120 125

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu  
130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp  
145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu  
165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser  
Page 1

180

185

190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro  
 195 200 205

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys  
 210 215 220

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro  
 225 230 235 240

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser  
 245 250 255

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp  
 260 265 270

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn  
 275 280 285

Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val  
 290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu  
 305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys  
 325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr  
 340 345 350

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr  
 355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu  
 370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu  
 385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys  
 405 410 415

Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu  
 420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly  
 435 440 445

Lys

<210> 2  
 <211> 219  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody light chain

<400> 2

Asp Val Leu Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly  
 1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Asn Ile Val His Ile  
 20 25 30

Asn Gly Asp Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly  
 85 90 95

Ser Leu Leu Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu  
 115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe  
 130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln  
 145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser  
 165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu  
 180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser  
 195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys  
 210 215

<210> 3  
 <211> 7  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 3

Phe Ser Gly Val Pro Asp Arg  
 1 5

<210> 4  
 <211> 5  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 4

Phe Thr Ile Ser Arg  
 1 5

<210> 5  
 <211> 13  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 5

Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys  
 1 5 10

<210> 6  
 <211> 11  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 6

Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg  
 1 5 10

<210> 7  
 <211> 25  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 7

His Ser Asp Gly Asn Phe Ala Phe Gly Tyr Trp Gly Gln Gly Thr Leu

1 5 10 15

Val Thr Val Ser Ser Ala Ser Thr Lys  
20 25

<210> 8  
<211> 22  
<212> PRT  
<213> Artificial

<220>  
<223> antibody fragment

<400> 8

Gly Leu Glu Trp Val Ala Thr Ile Ser Ser Ala Ser Thr Tyr Ser Tyr  
1 5 10 15

Tyr Pro Asp Ser Val Lys  
20

<210> 9  
<211> 28  
<212> PRT  
<213> Artificial

<220>  
<223> antibody fragment

<400> 9

Asn Ile Val His Ile Asn Gly Asp Thr Tyr Leu Glu Trp Tyr Leu Gln  
1 5 10 15

Pro Lys Gly Gln Ser Pro Gln Leu Leu Ile Tyr Lys  
20 25

<210> 10  
<211> 8  
<212> PRT  
<213> Artificial

<220>  
<223> antibody fragment

<400> 10

Ser Tyr Tyr Pro Asp Ser Val Lys  
1 5

<210> 11  
<211> 6  
<212> PRT  
<213> Artificial

<220>  
<223> antibody fragment

<400> 11

Gly Met Ser Trp Val Arg

1

5

<210> 12  
 <211> 12  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 12

Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr  
 1 5 10

<210> 13  
 <211> 15  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 13

Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Lys  
 1 5 10 15

<210> 14  
 <211> 13  
 <212> PRT  
 <213> Artificial

<220>  
 <223> antibody fragment

<400> 14

Asn Ile Val His Ile Asn Gly Asp Thr Tyr Leu Glu Trp  
 1 5 10